Winton Group
GALT icon

Winton Group’s Galectin Therapeutics GALT Stock Holding History

Winton Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$43.5K Buy
+11,200
New +$43.3K ﹤0.01% 1074
2019
Q4 		– Sell
-30,196
Closed -$111K – 1628
2019
Q3 		$111K Sell
30,196
-10,083
-25% -$36.4K ﹤0.01% 1454
2019
Q2 		$167K Buy
40,279
+10,986
+38% +$47.6K ﹤0.01% 1048
2019
Q1 		$150K Buy
+29,293
New +$141K ﹤0.01% 995

Other funds holding GALT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Wealthspire Advisors (New York)
Wealthspire Advisors (New York) New York $17.6B AUM 14.61% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Winton Group's GALT Position: Q3 2026 in Review

Winton Group opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 11,200 shares worth $43.5K. The stake represents ﹤0.01% of the portfolio and ranks #1074 among its holdings. This is a return to the name: Winton Group previously reported a position in GALT as recently as Q3 2019.

Winton Group first reported a position in GALT in Q1 2019 and has held it in 4 quarters since. The position peaked at $167K in Q2 2019. 83 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

  • Winton Group held 11,200 shares of Galectin Therapeutics worth $43.5K as of Q3 2026.
  • Galectin Therapeutics was a new Winton Group position in Q3 2026.
  • Galectin Therapeutics made up ﹤0.01% of Winton Group's portfolio in Q3 2026, its #1074 holding.
  • Winton Group first reported a position in Galectin Therapeutics in Q1 2019 and has held it in 4 quarters since.
  • Winton Group's Galectin Therapeutics position peaked at $167K in Q2 2019.
  • 83 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.